Search Results - V. P. Mikhin
- Showing 1 - 20 results of 26
- Go to Next Page
-
1
MILDRONATE POTENTIAL IN PATIENTS WITH CARDIOVASCULAR DISEASE by V. P. Mikhin, F. E. Khlebodarov
Published 2010-08-01.
Get full text
Article -
2
CYTOPROTECTOR ROLE IN THE MANAGEMENT OF ARTERIAL HYPERTENSION TREATED WITH ENALAPRIL by F. E. Khebodarov, V. P. Mikhin
Published 2009-10-01The study investigated the effects of cardiac cytoprotectors – mildronate and trimetazidine, combined with ACE therapy, on lipid peroxidation product levels, endothelial function, circadian blood pressure (BP) profile, left ventricular myocardium, and intracardiac hemodynamics in patients with arter...
Get full text
Article -
3
Mildronate effectiveness in post-hospital rehabilitation of patients with myocardial infarction by V. P. Mikhin, O. N. Koltsova
Published 2012-04-01Aim. To study the effects of mildronate, as a component of complex therapy, on left ventricular (LV) systolic and diastolic function and exercise capacity (EC) in myocardial infarction (MI) patients undergoing post-hospital rehabilitation. Material and methods. This open, randomized study included 2...
Get full text
Article -
4
CARDIOCYTOPROTECTORS' ROLE IN THE MANAGEMENT OF ISCHEMIC CHRONIC HEART FAILURE by V. P. Mikhin, V. V. Savelyeva
Published 2009-02-01.
Get full text
Article -
5
PATIENTS WITH ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOSPITALIZATION STRUCTURE AND ANTITHROMBOTIC THERAPY (RECVASA AF-KURSK REGISTRY) by V. P. Mikhin, Yu. V. Maslennikova, M. M. Loukianov
Published 2017-05-01Study objective. To assess the peculiarities of hospitalization of patients with AF in combination with CHD in the departments of the general therapeutic profile of a multidisciplinary hospital, the frequency of complications of various forms of AF, to analyze anticoagulant (AC) and antiplatelet (AP...
Get full text
Article -
6
COMPARATIVE EFFECTIVENESS OF CARDIOCYTE PROTECTORS IN COMPLEX MANAGEMENT OF ARTERIAL HYPERTENSION by F. E. Khlebodarov, V. P. Mikhin, A. V. Gorlova
Published 2009-08-01The study investigated the effects of cardiocyte protectors, mexicor and mildronate, in combination with ACE inhibitors, on blood levels of lipid peroxidation products, vascular endothelial function, circadian profile of blood pressure, and left ventricular morphology and function in patients with a...
Get full text
Article -
7
ENDOTHELIAL DYSFUNCTION AND ITS CORRECTION WIT CYTOPROTECTORS IN PATIENTS WITH STABLE EFFORT ANGINA AND ARTERIAL HYPERTENSION by F. E. Khlebodarov, P. Yu. Turikov, V. P. Mikhin
Published 2009-12-01The study compared the effects of cardiocytoprotectors (mildronate, trimetazidine) on endothelial function, physical stress tolerability, and circadian blood pressure (BP) profile in patients with arterial hypertension (AH; n=60) and stable angina (n=82), receiving anti-anginal therapy (beta-adrenob...
Get full text
Article -
8
MILDRONATE POTENTIAL FOR CARDIAC ARRHYTHMIA PREVENTION IN PERIOPERATIVE PERIODcardiac arrhythmias, ischemia, metabolic disturbances, cytoprotectors, antioxidants, operation-related... by V. P. Mikhin, N. A. Volkova, S. A. Sumin, P. A. Eremin
Published 2014-02-01Aim. To assess the effectiveness of Mildronate in the prevention of arrhythmias during the perioperative period of open cholecystectomy under intravenous multicomponent anesthesia.Material and methods. In total, 69 patients were divided into 3 groups: with concomitant coronary heart disease (CHD), w...
Get full text
Article -
9
Mildronate in cardiology practice – current evidence, ongoing research, and future perspectives by V. P. Mikhin, Yu. M. Pozdnyakov, F. E. Khlebodarov, O. N. Koltsova
Published 2012-02-01The review discusses the benefits and various practical aspects of the new cardioprotector mildronate use in cardiology. The latest evidence on the mildronate role in complex therapy of patients with stable angina, or patients in the rehabilitation period after myocardial infarction, is summarised.
Get full text
Article -
10
State stiffness parameters of the vascular wall in hypertensive patients complex therapy cytoprotector and sartans by V. P. Mikhin, U. A. Boldyreva, M. A. Chernyatina, N. I. Gromnatsky
Published 2015-10-01A randomized study of the state of stiffness parameters arteries wall (CAVI — cardio-ankle vascular index), AI (augmentation index) PEP (duration of the voltage of the left ventricle) using «VaSera-1000» («Fukuda Denshi», Japan) in primary hypertension patients (80) not treated with systemic antihyp...
Get full text
Article -
11
EFFECTIVENESS OF ROSUVASTATIN IN VERY HIGH RISK CARDIOVASCULAR PATIENTS IN THE ACTUAL OUTPATIENT PRACTICE by V. P. Mikhin, D. V. Nebieridze, N. M. Akhmedzhanov, Yu. A. Zhilyaeva
Published 2015-12-01Aim. To evaluate the comparative efficacy of Rosivastatin (Rosart) and atorvastatin in patients with very high grade of cardiovascular risk (CVR), arterial hypertension (AH) and chronic ischemic heart disease (CHD) in outpatient practice.Material and methods. Totally, 2 groups studied, of patients w...
Get full text
Article -
12
ARMYTHMIC ACTIVITY OF MYOCARDIUM AT DIFFERENT STAGES OF ANESTHESIA AND PERI-OPERATIVE PERIOD IN PATIENTS UNDERGOING CHOLECYSTECTOMY by S. A. Sumin, N. A. Volkova, V. P. Mikhin, E. N. Bogoslovskaya, P. A. Eremin
Published 2019-02-01Prevention of cardiovascular complications, which often result in fatal events in the peri-operative period, is one of the most crucial issues of modern anesthesiology.The objective: to investigate the changes in arrhythmic activity and conduction disorders during anesthesia and in the peri-operativ...
Get full text
Article -
13
Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy by V. P. Mikhin, O. A. Osipova, V. V. Vorotyntseva, D. N. Perutsky, N. I. Golovina
Published 2022-11-01Aim. To compare the effect of atorvastatin and rosuvastatin as part of complex therapy in patients with hypertension (HTN) with a high cardiovascular risk on the level of matrix metalloproteinases -1, -9 (MMP-1, MMP-9) and tissue inhibitors of metalloproteinases -1, -4 (TIMP-1, TIMP-4).Material and...
Get full text
Article -
14
PARAMETERS OF ARACHYDONIC ACID CYCLE METABOLISM IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ON THE BACKGROUND OF COMPLEX THERAPY OF OMEGA-3 POLYUNSATURATED FATTY ACIDS by V. P. Mikhin, A. I. Shveinov, M. A. Chernyatina, A. V. Kharchenko, G. V. Panchenko, N. I. Gromnatsky
Published 2017-12-01The aim of the study was to evaluate the effect of omega-3 polyunsaturated fatty acids on the main metabolic rates of the arachydonic acid cycle in patients with acute myocardial infarction in the context of traditional complex therapy. Materials and methods of research. We conducted an open, random...
Get full text
Article -
15
DOMESTIC MYOCARDIAL CYTOPROTECTOR EFFECTIVENESS AND ITS PHARMACODYNAMICS IN ACUTE MYOCARDIAL ISCHEMIA: CLINICAL RESULTS AND EXPERIMENTAL MODELS by V. P. Mikhin, M. V. Pokrovskyi, V. V. Gureev, O. A. Chernova, Yu. V. Alimenko, E. N. Bogoslovskaya
Published 2011-04-01Anti-ischemic effects of high-dose cardiac cytoprotector Mexicor (0,014 g/kg/d, 0,019 g/kg/d) were examined in rabbits with experimental myocardial infarction. In addition, anti-ischemic activity of Mexicor (0,4 g/d) was assessed in patients with acute coronary syndrome (ACS). It has been demonstrat...
Get full text
Article -
16
Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome by O. A. Osipova, V. P. Mikhin, A. I. Golovin, O. N. Belousova, D. N. Perutsky, P. K. Alferov, S. L. Konstantinov
Published 2022-07-01Aim. To conduct a comparative analysis of the effect of long-term pharmacotherapy (12 months) using a β-blocker (nebivolol) and its combination with eplerenone in patients after ST-segment elevation acute coronary syndrome (STE-ACS) with heart failure with mildly reduced ejection fraction (EF) (HFmr...
Get full text
Article -
17
Heart rate variability in patients with acute ST-segment elevation myocardial infarction after COVID-19 by V. P. Mikhin, O. A. Osipova, A. I. Gindler, A. S. Brizhaneva, N. V. Zaikina, M. P. Zaikina, T. A. Nikolenko, V. V. Savelyeva, M. A. Chernyatina
Published 2023-11-01Aim. To compare heart rate variability parameters in patients after a coronavirus disease 2019 (COVID-19) with acute ST elevation myocardial infarction (STEMI) during the inhospital and post-hospital periods.Material and methods. A total of 140 patients with STEMI were divided into 2 groups: I — pat...
Get full text
Article -
18
HYPOLIPIDEMIC AND PLEIOTROPIC EFFICACY OF ROSUVASTATIN IN ARTERIAL HYPERTENSION PATIENTS OF HIGH CARDIOVASCULAR RISK IN LONG-TERM OUTPATIENT FOLLOW-UP by V. P. Mikhin, Yu. A. Zhilyaeva, V. V. Vorotyntseva, D. V. Nebieridze, N. M. Akhmedzhanov, D. A. Vasil’eva, M. A. Chernyatina, N. A. Gromnatsky
Published 2016-12-01Aim. To evaluate the pleiotropical and hypolipidepmic efficacy of generic rosuvastatin (Rosucard) comparing with atorvastatin in arterial hypertension patients (AH) with high and very high cardiovascular risk (CVR) during the long-term usage in outpatient circumstances. Material and methods. Totally...
Get full text
Article -
19
THE CONTROL OF INTERNATIONAL NORMALISED RATIO IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH WARFARIN IN OUTPATIENT AND HOSPITAL SETTINGS: DATA FROM RECVASA REGISTRIES by M. M. Loukianov, S. Yu. Martsevich, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, T. A. Gomova, M. N. Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, M. A. Bichurina, L. A. Matskevich, E. N. Belova, V. G. Klyashtorny, E. V. Kudryashov, A. D. Deev, O. M. Drapkina, s. A. Boytsov
Published 2018-03-01Am. To study in the RECVASA registers the availability of data about the international normalized ratio (INR) indicator and achievement of its target values in outpatient and hospital practice in patients with atrial fibrillation (AF) receiving anticoagulant therapy with warfarin.Material and method...
Get full text
Article -
20
Modern antihypertensive therapy: the effectiveness of a unique Russian fixed-dose combination of ramipril and indapamide by A. O. Konradi, S. V. Nedogoda, A. O. Nedoshivin, L. G. Ratova, R. A. Libis, G. P. Arutyunov, N. Yu. Borovkova, A. S. Galyavich, Yu. I. Grinshteyn, D. V. Duplyakov, V. V. Kashtalap, Yu. M. Lopatin, N. P. Lyamina, S. V. Malchikova, V. P. Mikhin, G. I. Nechaeva, O. D. Ostroumova, T. M. Ripp, G. A. Chumakova, I. I. Shaposhnik, V. V. Yakusevich
Published 2020-04-01Experts consensus of the Russian Cardiology Society (RSC)
Get full text
Article